Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Labs (ABT)
NYSE:ABT
Abbott Labs (ABT) Stock Price & Analysis
7,069 Followers
ABT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$88.80 - $121.04
Previous Close$109.21
Volume7.73M
Average Volume (3M)5.75M
Market Cap
$183.13B
Enterprise Value$196.57B
Total Cash (Recent Filing)$7.28B
Total Debt (Recent Filing)$14.68B
Price to Earnings (P/E)33.4
Beta0.71
Next Earnings
Apr 17, 2024EPS Estimate
$0.96Last Dividend Ex-Date
Apr 12, 2024Dividend Yield1.91%
Share Statistics
EPS (TTM)3.27
Shares Outstanding1,735,184,289
10 Day Avg. Volume4,631,938
30 Day Avg. Volume5,747,384
Standard Deviation0.06
R-Squared0.41
Alpha0.00038
Financial Highlights & Ratios
Price to Book (P/B)31.10
Price to Sales (P/S)4.71
Price to Cash Flow (P/CF)15.60
P/FCF Ratio19.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.90
Enterprise Value/Gross Profit8.88
Enterprise Value/Ebitda18.64
Forecast
1Y Price Target
$127.21Price Target Upside20.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Abbott Labs News
Bulls Say, Bears Say
Bulls Say
Market ExpansionABT is regaining ground in the US infant formula market and has drivers for margin improvement.
Product LaunchThe launch of several new products by ABT is likely to enhance the company's growth.
Regulatory ApprovalABT's TriClip tricuspid repair device received FDA approval, which is expected to boost its market adoption due to its favorable adverse event profile and eligibility for New Technology Add-On Payment.
Bears Say
Legal And Regulatory IssuesThe formula business of ABT faces litigation risk, although it is deemed manageable.
Market Share And CompetitionForecasted US TriClip revenue shows a market share shift favoring EW over ABT by 2028.
Product Efficacy And LimitationsSome panelists expressed concerns that TriClip procedure may limit future treatment options like defibrillators/pacemakers or afib ablation.
---
Ownership Overview
2.80% Insiders
26.14% Mutual Funds
18.69% Other Institutional Investors
52.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABT FAQ
What was Abbott Labs’s price range in the past 12 months?
Abbott Labs lowest stock price was $88.80 and its highest was $121.04 in the past 12 months.
What is Abbott Labs’s market cap?
Currently, no data Available
When is Abbott Labs’s upcoming earnings report date?
Abbott Labs’s upcoming earnings report date is Apr 17, 2024 which is yesterday.
How were Abbott Labs’s earnings last quarter?
Abbott Labs released its earnings results on Jan 24, 2024. The company reported $1.19 earnings per share for the quarter, the consensus estimate of $1.19 by $0.
Is Abbott Labs overvalued?
According to Wall Street analysts Abbott Labs’s price is currently Undervalued.
Does Abbott Labs pay dividends?
Abbott Labs pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 1.91%. See more information on Abbott Labs dividends here
What is Abbott Labs’s EPS estimate?
Abbott Labs’s EPS estimate is $0.96.
How many shares outstanding does Abbott Labs have?
Abbott Labs has 1,735,184,300 shares outstanding.
What happened to Abbott Labs’s price movement after its last earnings report?
Abbott Labs reported an EPS of $1.19 in its last earnings report, expectations of $1.19. Following the earnings report the stock price went down -2.839%.
Which hedge fund is a major shareholder of Abbott Labs?
Among the largest hedge funds holding Abbott Labs’s share is Fisher Asset Management LLC. It holds Abbott Labs’s shares valued at 1B.
---
Abbott Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.21 (20.18% Upside)
$127.21 (20.18% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 164.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 94%
Bearish news 6%
Bearish news 6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.18%
12-Months-Change
Fundamentals
Return on Equity
15.15%
Trailing 12-Months
Asset Growth
-1.64%
Trailing 12-Months
Company Description
Abbott Labs
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
ABT Company Deck
---
ABT Earnings Call
Q4 2024
0:00 / 0:00
---
ABT Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
ABT Stock 12 Months Forecast
Average Price Target
$127.21
▲(20.18% Upside)
Technical Analysis
Best Analysts Covering ABT
1 Year
1 Year Success Rate
40/46 ratings generated profit
1 Year Average Return
+19.30%
reiterated a buy rating 4 months ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +19.30% per trade.
---